Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;45(5):580-583.
doi: 10.1111/1346-8138.14231. Epub 2018 Jan 21.

Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus

Xiaoyun Tan  1   2 , Jing Zhang  1   2 , Shaoyi Zhou  1   2 , Zhenyin Liu  1   2 , Tao Zhang  1   2 , Jiejun Xia  1   2
Affiliations

Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus

Xiaoyun Tan et al. J Dermatol. 2018 May.

Abstract

Vascular tumors associated with Kasabach-Merritt phenomenon (KMP) are life-threatening and the mortality is as high as 10-30%. Steroids are considered the primary choice for drug therapy. However, there are many steroid-resistant cases. In the present study, analyzed data are presented to support the use of sirolimus in clinical practise for the treatment of corticosteroid-resistant vascular tumors with KMP in eight infants between June 2015 and April 2017 in a single hospital. The time to initial response was 6.8 ± 2.7 days. The average stabilization time for the platelet count was 19.1 ± 8.5 days. At the time of publication, the average duration of sirolimus treatment was 14.1 ± 4.0 months, and the average time for sirolimus treatment as a single agent was 12.6 ± 4.2 months. The side-effects were tolerable and included oral ulcer, fever, pain, skin rash and transient ascension of serum transaminase and cholesterol. Our study indicated that sirolimus therapy is an effective and safe method for the treatment of corticosteroid resistant vascular tumors associated with KMP in infants.

Keywords: Kasabach-Merritt phenomenon; hemangioendothelioma; mammalian target of rapamycin inhibitor; sirolimus; tufted angioma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A patient aged 18 months with Kasabach–Merritt phenomenon in the maxillofacial region, neck and anterior chest wall. (a–b) Magnetic resonance imaging (MRI) examination showed extensive lesions in the right and left maxillofacial region, neck and anterior chest wall with unclear boundaries, a high signal intensity on enhanced T1‐weighted images and tracheal compression. The patient had undergone four transcatheter arterial embolizations, more than 2 years of steroid use and intermittent vincristine therapy before sirolimus treatment. However, the condition was recurrent, and the platelet level continued to decline. (c–d) MRI re‐examination after 10 months of sirolimus therapy revealed that the lesions had disappeared from the maxillofacial region, neck and anterior chest wall.
See this image and copyright information in PMC

References

    1. Croteau SE, Liang MG, Kozakewich HP et al Kaposiform hemangioendothelioma: atypical features and risks of Kasabach‐Merritt phenomenon in 107 referrals. J Pediatr, 2013; 162: 142–147. - PMC - PubMed
    1. Drolet BA, Trenor CC, Brandão LR et al Consensus‐Derived Practice Standards Plan for Complicated Kaposiform Hemangioendothelioma. J Pediatr 2013; 163: 285–291. - PubMed
    1. Tan X, Chen M, Zhang J et al Treatment of corticosteroid‐resistant vascular tumors associated with the Kasabach‐Merritt phenomenon in infants: an approach with transcather arterial emblization plus vincristine therapy. J Vasc Interv Radiol 2016; 27: 569–575. - PubMed
    1. Yasui N, Koh K, Kato M et al Kasabach–Merritt phenomenon: a report of 11 cases from a single institution. J Pediatr Hematol Oncol 2013; 35: 554–558. - PubMed
    1. Wang Z, Li K, Yao W et al Steroid‐Resistant kaposiform hemangioendothelioma: a Retrospective Study of 37 patients treated with vincristine and long‐term follow‐up. Pediatr Blood Cancer 2015; 62: 577–580. - PubMed

MeSH terms